![[APHA]](/images/logo_apha.svg){kind=logo}
Australian cancer patients will have greater access to advanced treatment and clinical trials thanks to a new partnership.
Icon Cancer Centre is teaming up with Omico, a national not-for-profit organisation that aims to provide people with personalised care through its screening programs.
"This partnership addresses a critical gap in patient access to precision oncology," said Icon Cancer Centre Australia and New Zealand's CEO, Paul Fenton.
"This marks Omico's first partnership with a national private cancer care provider, creating a new model for integrating precision oncology trials within community-based cancer care and supporting our mission to deliver the best care possible as close to homes as possible."
The partnership will leverage Icon's national network of 40 cancer centres and Omico's expertise in molecular profiling and targeted therapy trials.
Omico's PrOSPeCT program is Australia's largest precision oncology initiative, giving free comprehensive genomic profiling to 23,000 patients with advanced, incurable or poor-prognosis cancers.
Along with its cancer screening program, it helps clinicians to provide tailored treatment options for their patients.
Icon has 40 cancer centres across Australia
Icon Cancer Centre's Director of Medical Oncology, Associate Professor Louise Nott, expects the collaboration to create clinical improvements.
"Every cancer diagnosis is different, and genomic testing is transforming the way we treat cancer and deliver truly personalised care," she said.
"By identifying the unique drivers of a patient's cancer, we can match them with targeted therapies and clinical trials that can offer improved outcomes.
"Partnering with Omico is a crucial step in evolving clinician access to genomic-guided treatment and ultimately ensuring patients have better access to innovative treatments."
Omico CEO Ian Black said the partnership would also expand clinical trial availability across Icon's network, giving more patients wider access to advanced therapies and the opportunity to contribute to leading-edge research.
"We're focused on building capacity beyond metropolitan centres so people in regional and rural communities have the same opportunities for cutting-edge cancer care as those in our cities – equity of access must be the standard for every Australian affected by cancer," Mr Black said.
Read more: Global recognition for Icon trials team
Read more: Icon commits to cellular therapy expansion
Previous Safety And Quality:
10/4/2025 New book empowers lymphoedema patients